SOAT1 and COVID-19: Finally, inhibitors of cytokine signaling pathways such as the JAK/STAT inhibitors (eg, baricitinib, ruxolitinib, and tofacitinib) and non-specific tyrosine kinase inhibitors (eg, imatinib) have also shown promise in modulating the immune response in COVID-19.